Linsitinib (OSI-906)

Catalog No.S1091

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Cited by 76 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 539(7630):570-574

PubMed: 27820945 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )
PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )
BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	NWGyNI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3v2TGlEPTB;MD6wNlgxPiEQvF2=	MlG5V2FPT0WU
KS-1	M3rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF22VVlKSzVyPUCuNFM5OzVizszN	NInXVm9USU6JRWK=
TE-11	NW\DSmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLjZlB7UUN3ME2wMlA4QDJ{IN88US=>	MUHTRW5ITVJ?
EW-1	NEnCfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn2S5lKSzVyPUCuNFg2QDVizszN	M2P0bnNCVkeHUh?=
HMV-II	NEC5bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmS5TWM2OD1yLkC4PFQ3KM7:TR?=	NUPpZlZ{W0GQR1XS
COLO-205	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMUC0OVQh\|ryP	MlqzV2FPT0WU
ES1	M4Lubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[wb\|duUUN3ME2wMlExPjl4IN88US=>	MXTTRW5ITVJ?
GDM-1	M1;hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;UTWM2OD1yLkGzOlczKM7:TR?=	M1HWb3NCVkeHUh?=
ML-2	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnS0TWM2OD1yLkG1PFk3KM7:TR?=	NVLjXlZmW0GQR1XS
Saos-2	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMU[1NlYh\|ryP	NECxNJFUSU6JRWK=
NCI-H1355	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnVTWM2OD1yLkG4NVM2KM7:TR?=	NHrRfWdUSU6JRWK=
G-401	M2XaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\tTWM2OD1yLkG4NlMh\|ryP	MWLTRW5ITVJ?
EW-16	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjITnJKSzVyPUCuNVg4PzdizszN	MkjjV2FPT0WU
EW-7	M1LK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHntPWpKSzVyPUCuNVg5QDFizszN	NUT4UYgyW0GQR1XS
NCI-H727	NEPCXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PmXWlEPTB;MD6xPVc6PCEQvF2=	MoTsV2FPT0WU
LCLC-97TM1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzZNoQyUUN3ME2wMlIxQTV3IN88US=>	MX\TRW5ITVJ?
NCI-H650	NV75UlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\IVWlEPTB;MD6yNVM5PCEQvF2=	NIrW[mxUSU6JRWK=
NCI-H2122	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMkOyPVkh\|ryP	NHnCbVJUSU6JRWK=
SK-N-DZ	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMkO2PVgh\|ryP	M1HRRnNCVkeHUh?=
HT-29	M4nubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\FUWlEPTB;MD6yOFI1QCEQvF2=	MoLLV2FPT0WU
LB771-HNC	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP1PZBKSzVyPUCuNlU6OTVizszN	MUXTRW5ITVJ?
HT-144	M4XH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\lXmlEPTB;MD6yOlE6OSEQvF2=	NF7pRW9USU6JRWK=
LAN-6	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7LSG1KSzVyPUCuNlY{PDhizszN	MmnYV2FPT0WU
EW-18	M1HCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7le5B7UUN3ME2wMlI4ODBzIN88US=>	M1i5[HNCVkeHUh?=
LS-1034	M{HaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETocm9KSzVyPUCuNlcyOzJizszN	M1nyeHNCVkeHUh?=
EW-11	NYro[YVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n6OGlEPTB;MD6yPFQ{OiEQvF2=	NV64OJdLW0GQR1XS
SNU-C1	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMkmzNVMh\|ryP	MnnyV2FPT0WU
RS4-11	Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrReVlKSzVyPUCuN\|M4PThizszN	MXrTRW5ITVJ?
ES4	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwNEGwN\|gh\|ryP	MnH0V2FPT0WU
COLO-320-HSR	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfHTWM2OD1yLkSxN\|Y5KM7:TR?=	MmS3V2FPT0WU
NB10	NFT3OHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fuTGlEPTB;MD60OVQ{PyEQvF2=	NV24PJR3W0GQR1XS
BFTC-905	NHnqXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwNE[3OVgh\|ryP	MkTpV2FPT0WU
A375	NHTSPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Xac2lEPTB;MD60O\|YyPyEQvF2=	M1rNU3NCVkeHUh?=
SJRH30	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLoV5g3UUN3ME2wMlUxQDJ{IN88US=>	NYr2VW8{W0GQR1XS
NOS-1	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwNUKyOlch\|ryP	MYPTRW5ITVJ?
SIG-M5	M4DDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwNUO1OVch\|ryP	MnTHV2FPT0WU
DOK	NV2yT25qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInCUmZKSzVyPUCuOVU3KM7:TR?=	NH2xNGdUSU6JRWK=
NB69	NImzeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPLXIhKSzVyPUCuOVgzPTdizszN	M3XOXHNCVkeHUh?=
SK-NEP-1	NY\TT2djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjRcnpKSzVyPUCuOlAzOzZizszN	Ml\MV2FPT0WU
SK-MM-2	NYnnOnpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwNkW0PVEh\|ryP	NVPZfIxFW0GQR1XS
NCI-H358	M{[wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnzTW5KSzVyPUCuOlcxQDJizszN	M1jPc3NCVkeHUh?=
RH-1	NIf6TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\MTlBKSzVyPUCuO\|Q5PTlizszN	MXjTRW5ITVJ?
NH-12	NXnoTYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLjTWM2OD1yLke2NFQ3KM7:TR?=	MYjTRW5ITVJ?
TE-12	NYq3UFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fMTmlEPTB;MD63OlQ5PiEQvF2=	NI\2VppUSU6JRWK=
COLO-668	NUD1cIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHvNpRSUUN3ME2wMlg1PjZ4IN88US=>	NGnSdIdUSU6JRWK=
PANC-08-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLJ[FF3UUN3ME2wMlg3Ozd5IN88US=>	MVvTRW5ITVJ?
HCC2998	NWeySlE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fOT2lEPTB;MD64PFI3OyEQvF2=	MoGwV2FPT0WU
ABC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXYRpBKSzVyPUCuPVA{PTJizszN	Mn;CV2FPT0WU
ES6	NXP0fIxwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjKfZV7UUN3ME2wMlkyODZ4IN88US=>	NIL1RlJUSU6JRWK=
SNU-387	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn0TWM2OD1yLkm5N\|k{KM7:TR?=	MorEV2FPT0WU
CMK	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfETWM2OD1yLkm5PVI6KM7:TR?=	NV76TJN3W0GQR1XS
SJSA-1	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTFwMEO2OVMh\|ryP	NVKwN5RLW0GQR1XS
SIMA	NXfobnFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvXXphKSzVyPUGuNFY5OjVizszN	NF\ldndUSU6JRWK=
ES3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:5Z2tKSzVyPUGuNVIzQTdizszN	M37qdHNCVkeHUh?=
IGROV-1	M1LUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rJ[GlEPTB;MT6xOVQ1PCEQvF2=	NULEPZROW0GQR1XS
MEL-JUSO	NXjr[mNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrSTWM2OD1zLkG1O\|U6KM7:TR?=	M13L[HNCVkeHUh?=
T84	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXiXYJKSzVyPUGuNlA6OTRizszN	MYXTRW5ITVJ?
CAL-85-1	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjtW\|BJUUN3ME2xMlI{OTN6IN88US=>	NWXGUml[W0GQR1XS
RD	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfhTWM2OD1zLkK2OFU2KM7:TR?=	NIjISmxUSU6JRWK=
TE-8	NXzC[ZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7BTWM2OD1zLkOxOFYzKM7:TR?=	M2PHSXNCVkeHUh?=
L-363	NFr2TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTFwM{SyNFgh\|ryP	NHG4XIxUSU6JRWK=
EKVX	NXHXSXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoCyTWM2OD1zLkO0OVY5KM7:TR?=	M3TY[XNCVkeHUh?=
SK-MEL-3	NXPFUVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LiZmlEPTB;MT60PFU2PiEQvF2=	MWjTRW5ITVJ?
TGBC24TKB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHZTWM2OD1zLkWwNVk{KM7:TR?=	NWizd5JDW0GQR1XS
NCI-H1770	NIW5OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7iTWM2OD1zLkWxNVE{KM7:TR?=	NVX2d4xKW0GQR1XS
HuH-7	M4\QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vtOWlEPTB;MT62NFA6QCEQvF2=	M{jSbnNCVkeHUh?=
HL-60	M4S5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDUWGU2UUN3ME2xMlY3QTJ6IN88US=>	MWPTRW5ITVJ?
TE-1	NUC5PXhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LmV2lEPTB;MT63NFk1PSEQvF2=	NYTyN5dGW0GQR1XS
LC-2-ad	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDuTWM2OD1zLkezPFg4KM7:TR?=	M{XGTnNCVkeHUh?=
LB647-SCLC	NXOyOFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHQdXNUUUN3ME2xMlc3PTh\|IN88US=>	NVjHPJZNW0GQR1XS
NCI-H2171	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFwN{e3NVYh\|ryP	MnjJV2FPT0WU
SK-PN-DW	NFvGb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlWxTWM2OD1zLkmxNlk5KM7:TR?=	MWrTRW5ITVJ?
MC-IXC	NHi3OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnpWItxUUN3ME2xMlk5QThizszN	M3LvO3NCVkeHUh?=
LS-513	NYPod\|c6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPHTWM2OD1{LkC1N\|A2KM7:TR?=	MULTRW5ITVJ?
EW-3	NYD4S4htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJwMEm4OFQh\|ryP	NYH1e4NkW0GQR1XS
OPM-2	NYfMTIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLacHV7UUN3ME2yMlExOiEQvF2=	Ml7WV2FPT0WU
LP-1	M1XKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHyTWM2OD1{LkK1PFA4KM7:TR?=	MUTTRW5ITVJ?
LU-134-A	M{fqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r4e2lEPTB;Mj6yO\|ch\|ryP	MmPZV2FPT0WU
CP66-MEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nLZ2lEPTB;Mj6yPVAyPCEQvF2=	NHO2TXVUSU6JRWK=
HCC1143	NIPWdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJwNEWzOlgh\|ryP	Ml3SV2FPT0WU
LOXIMVI	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWC1bWZUUUN3ME2yMlYxOjFizszN	M1XwcXNCVkeHUh?=
TE-10	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\wUmlEPTB;Mj63NFg{QCEQvF2=	M4LrNHNCVkeHUh?=
NCI-H1882	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvBRZFEUUN3ME2yMlc2OjJ5IN88US=>	MVTTRW5ITVJ?
CHP-126	NIPXe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLKUmdKSzVyPUKuO\|Y{OTdizszN	NFjEXWxUSU6JRWK=
NCI-H1623	NGfFOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJwOUKwNlQh\|ryP	MV7TRW5ITVJ?
GB-1	M4HYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjyXXJ3UUN3ME2yMlk{PDB2IN88US=>	NYHYbZNmW0GQR1XS
RCC10RGB	M{D6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLlTWM2OD1{Lkm1NlgyKM7:TR?=	M2\XbHNCVkeHUh?=
NCI-H2141	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzIbXFKSzVyPUKuPVY5QTZizszN	MUfTRW5ITVJ?
GI-ME-N	NH[xe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHLPYFIUUN3ME2zMlAxPTZ3IN88US=>	NEDMOItUSU6JRWK=
NCI-H526	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDEZoJKSzVyPUOuNFQxQDVizszN	NWrYUGQ6W0GQR1XS
NCI-H747	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3odJJKSzVyPUOuNFQ6QTJizszN	NXvvWXNVW0GQR1XS
SNU-423	NY\ENnhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fGfWlEPTB;Mz6yNFMyOyEQvF2=	NH;YWZBUSU6JRWK=
A427	NELKV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXWTWZKSzVyPUOuNlU3QTlizszN	NHvmfYxUSU6JRWK=
CAL-12T	M4W1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTNwNEC3NVMh\|ryP	MmTsV2FPT0WU
LU-99A	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\ETWlEPTB;Mz60O\|ExPSEQvF2=	MlzJV2FPT0WU
MS-1	NH65NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;EXVlKSzVyPUOuOVM1OjlizszN	M1H6OnNCVkeHUh?=
SK-LU-1	NXvzU5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTyTWM2OD1\|Lke2Nlk2KM7:TR?=	MkHFV2FPT0WU
SW837	NGHnc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\2eZdXUUN3ME2zMlc3OzN\|IN88US=>	MoPTV2FPT0WU
ES8	M2j3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnnb3h5UUN3ME2zMlg{QDd5IN88US=>	NWHkV\|FRW0GQR1XS
MZ2-MEL	M2XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\Pc2lEPTB;Mz65NlA5PiEQvF2=	MUTTRW5ITVJ?
TGW	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXmTWM2OD12LkCxN\|EyKM7:TR?=	Ml3jV2FPT0WU
GP5d	M1fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUG0XHA{UUN3ME20MlA2OzZ{IN88US=>	NXLpcXlDW0GQR1XS
BB49-HNC	NWrQfot{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHISIVKUUN3ME20MlE2OjF\|IN88US=>	NFryWJdUSU6JRWK=
NB13	M4nlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nBWmlEPTB;ND6yOlg5PyEQvF2=	NELadY5USU6JRWK=
NTERA-S-cl-D1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrFTWM2OD12LkK4OlE2KM7:TR?=	NYq2S48xW0GQR1XS
NCI-H1648	NF7He5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUOxSmFGUUN3ME20MlI6QDF7IN88US=>	Ml\QV2FPT0WU
LCLC-103H	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\O[mlEPTB;ND6zNlE6PSEQvF2=	MlfuV2FPT0WU
LS-411N	M1m4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zLSGlEPTB;ND60OFg5PSEQvF2=	MXXTRW5ITVJ?
NCI-H1092	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTRwNEW2PFch\|ryP	MW\TRW5ITVJ?
PANC-10-05	NHHodXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTRwNkm4OEDPxE1?	MXrTRW5ITVJ?
DK-MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETEUI5KSzVyPUSuPFA6OzNizszN	MVrTRW5ITVJ?
OVCAR-5	NWGzW5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfNc4tSUUN3ME20MlgyOjJ4IN88US=>	MULTRW5ITVJ?
CAL-39	M1TwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrpVWRKSzVyPUSuPFc3PyEQvF2=	MXTTRW5ITVJ?
TE-441-T	NV7Qb5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTRwOUC1N\|ch\|ryP	NF\4ZmpUSU6JRWK=
MOLT-16	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3uyN2lEPTB;ND65OVI2OyEQvF2=	Mn7PV2FPT0WU
MCF7	NVnvcGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvrbW9JUUN3ME21MlE1PTF5IN88US=>	MVHTRW5ITVJ?
CAPAN-1	NEn5UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP5TWM2OD13LkK1O\|A4KM7:TR?=	M{[0XHNCVkeHUh?=
PSN1	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXriclhpUUN3ME21MlI4OjN3IN88US=>	NVjzZnl[W0GQR1XS
NCI-H292	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnsWIZKSzVyPUWuN\|AxPDRizszN	M4XYcnNCVkeHUh?=
CPC-N	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3vTWM2OD13LkO5OFE6KM7:TR?=	M3PvTXNCVkeHUh?=
DoTc2-4510	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjhTWM2OD13LkS1N\|cyKM7:TR?=	NH3VS3hUSU6JRWK=
LB1047-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;SUopKSzVyPUWuOVU6OzNizszN	NV7OZ5ZsW0GQR1XS
MHH-ES-1	NYXHOXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPtTWM2OD13LkW5PVA4KM7:TR?=	MXzTRW5ITVJ?
NMC-G1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTVwN{CyNlch\|ryP	MnXZV2FPT0WU
SW1710	NFLYbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTVwN{S3OVEh\|ryP	M3fvUnNCVkeHUh?=
YAPC	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDnS\|B1UUN3ME21Mlc3OjBzIN88US=>	NUKyN2U{W0GQR1XS
22RV1	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTVwOECwNVkh\|ryP	MW\TRW5ITVJ?
COLO-679	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTVwOEi5OFgh\|ryP	M2TvTXNCVkeHUh?=
TCCSUP	NX3FVFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjETWM2OD13LkmzNlU6KM7:TR?=	M3;6WXNCVkeHUh?=
C2BBe1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTVwOUO5O{DPxE1?	NUPtR\|FUW0GQR1XS
TE-15	NWXHV\|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDPTWM2OD14LkC2OlA2KM7:TR?=	NFy3fWJUSU6JRWK=
SCLC-21H	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;md4tKSzVyPU[uNVA5PDNizszN	MWLTRW5ITVJ?
EoL-1-cell	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\5OphGUUN3ME22MlE3PTZ\|IN88US=>	NXSzdpVEW0GQR1XS
NKM-1	NGfFPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIOxWINKSzVyPU[uNVY4OSEQvF2=	MYnTRW5ITVJ?
NCI-H1304	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTZwMke0Nlgh\|ryP	M3W0fnNCVkeHUh?=
NB6	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTZwMkm2NlIh\|ryP	NUTwdnplW0GQR1XS
NALM-6	NYHQSYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LHTWlEPTB;Nj6zN\|I{KM7:TR?=	MmLtV2FPT0WU
NCI-H522	NF\ISWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[yXW1tUUN3ME22MlM{OzB4IN88US=>	MV7TRW5ITVJ?
MV-4-11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPFTWM2OD14LkO3NFc6KM7:TR?=	MX;TRW5ITVJ?
LB2241-RCC	M1rZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWwSXdvUUN3ME22MlM5PjZ5IN88US=>	NYr4e\|dbW0GQR1XS
NCI-H1417	NFjUfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTZwNEC4OFch\|ryP	NXfKcmZYW0GQR1XS
HT-1197	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYe1O4t{UUN3ME22MlU4OTJ{IN88US=>	NXPHUXZjW0GQR1XS
P30-OHK	NHjlU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTZwNkK3O{DPxE1?	NFPNWpZUSU6JRWK=
ALL-PO	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLTVpdwUUN3ME22MlcyQTF4IN88US=>	NHPtcHhUSU6JRWK=
OVCAR-4	NUnnV3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTZwN{W0NFUh\|ryP	MYrTRW5ITVJ?
HCC2157	NGOyW\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjZRmh7UUN3ME22Mlc4PDd3IN88US=>	MnfrV2FPT0WU
NCI-H838	NG\mUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[wTWM2OD14Lkm2OFkh\|ryP	NH74eFVUSU6JRWK=
NCI-H1299	M{PMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DjemlEPTB;Nj65O\|A6KM7:TR?=	NV\H[ldWW0GQR1XS
SW954	NGHRbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzKTWM2OD15LkKwNFY5KM7:TR?=	M1n5[XNCVkeHUh?=
NCI-H441	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW2N\|c6UUN3ME23MlM1ODZ3IN88US=>	NIG0dJpUSU6JRWK=
SK-MEL-2	NHuwXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fjc2lEPTB;Nz60PFM4OyEQvF2=	Moj0V2FPT0WU
KARPAS-45	NWfUNG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLoOYtKSzVyPUeuOlU6OjlizszN	MXHTRW5ITVJ?
CAL-54	NFr5ZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jZXWlEPTB;Nz64Nlk4PyEQvF2=	NIKwZYtUSU6JRWK=
KYSE-180	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjWRW4{UUN3ME23Mlg5QTRzIN88US=>	NVPqe2M6W0GQR1XS
NCI-H187	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfPUGdKSzVyPUeuPVU6PDdizszN	MYfTRW5ITVJ?
RT-112	M3jwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRThwMEm2O\|ch\|ryP	NFLw[JNUSU6JRWK=
NCI-H1437	NI[zbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHQTWM2OD16LkC5O\|k2KM7:TR?=	MlO4V2FPT0WU
SNU-449	NX\SZYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUC1NIdXUUN3ME24MlI5Ojd{IN88US=>	M2e0cXNCVkeHUh?=
HCC1187	NXT0[FJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\Dc4tzUUN3ME24MlI6OzlzIN88US=>	Ml;pV2FPT0WU
NCI-H2030	NEnhUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRThwM{e3NVQh\|ryP	M4PLdXNCVkeHUh?=
HuO-3N1	M1nEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\QRmlEPTB;OD6zO\|g1PCEQvF2=	NF3uUoRUSU6JRWK=
COLO-792	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjpdJNKSzVyPUiuOFE2OjdizszN	NGXWO4tUSU6JRWK=
MIA-PaCa-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRThwOEW1NFgh\|ryP	NInZPW1USU6JRWK=
SK-N-FI	M2rhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknITWM2OD17LkC0NlUh\|ryP	NHPuV3VUSU6JRWK=
MMAC-SF	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnRRlNKSzVyPUmuNFk4PTFizszN	MYfTRW5ITVJ?
NCI-H28	NUDoW3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTlwMUC0Olkh\|ryP	NEL4PYtUSU6JRWK=
ETK-1	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rTUWlEPTB;OT6yPVk4PCEQvF2=	MoqwV2FPT0WU
NCI-H1993	NWrYdm03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPRRld4UUN3ME25MlQ1OjZzIN88US=>	M{[4[HNCVkeHUh?=
no-11	NXn1U3ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\lXnYxUUN3ME25MlQ4OTJizszN	MnvnV2FPT0WU
ChaGo-K-1	NF\4UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfa[mlKSzVyPUmuOVE2QDNizszN	NVjQ[WdEW0GQR1XS
NCCIT	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTlwNUOxOlkh\|ryP	M3nGSHNCVkeHUh?=
SAS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HscmlEPTB;MUCuNlQ5KM7:TR?=	M3\OW3NCVkeHUh?=
A673	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;TUWlEPTB;MUCuN\|cxPCEQvF2=	NFXQbmlUSU6JRWK=
NCI-H1522	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LjNGlEPTB;MUCuN\|cxPyEQvF2=	NIO1[3hUSU6JRWK=
NCI-H810	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfwZoZVUUN3ME2xNE4{QTB5IN88US=>	MULTRW5ITVJ?
IST-MES1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTFyLkS1OlQh\|ryP	M{LnO3NCVkeHUh?=
GR-ST	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFyLkWwNlQh\|ryP	MVLTRW5ITVJ?
SUP-T1	M1TaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\hdHFKSzVyPUGwMlc{OTdizszN	M3n1OnNCVkeHUh?=
NB5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XFfWlEPTB;MUCuPVAzOiEQvF2=	MXTTRW5ITVJ?
MZ1-PC	M4\QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3PW\|RtUUN3ME2xNE46PTdzIN88US=>	M{WxN3NCVkeHUh?=
SK-CO-1	M4H4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXJTFZVUUN3ME2xNE46QTNzIN88US=>	Mn:zV2FPT0WU
Capan-2	NG\O[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPnR2xKSzVyPUGxMlMyQThizszN	MnrBV2FPT0WU
697	MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkCxTWM2OD1zMT62O\|U4KM7:TR?=	NGLGTZdUSU6JRWK=
REH	M2OzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFzLke0OVEh\|ryP	M4\CR3NCVkeHUh?=
GI-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFzLki2NVUh\|ryP	M2XGOnNCVkeHUh?=
BB65-RCC	NV31PG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF{LkC5NVYh\|ryP	NGrWSI1USU6JRWK=
NCI-H1651	M2XaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTF{LkK0O\|gh\|ryP	M4DYVHNCVkeHUh?=
NCI-H1618	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vCV2lEPTB;MUKuN\|k4PiEQvF2=	NFnrWnlUSU6JRWK=
NCI-H2081	NF7YUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfubJRKSzVyPUGyMlYyPDFizszN	NXLIZWRWW0GQR1XS
GCIY	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTF{LkeyNVMh\|ryP	MmnBV2FPT0WU
NY	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIftTIpKSzVyPUGzMlA3PDNizszN	NIi5WXpUSU6JRWK=
PANC-03-27	NFv2R\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;G[XhkUUN3ME2xN{4xQDB5IN88US=>	NHXkZ2pUSU6JRWK=
BHY	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTuTYV4UUN3ME2xN{4zOTJzIN88US=>	Ml;BV2FPT0WU
SK-OV-3	NH7tcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HaeGlEPTB;MUOuN\|c3OyEQvF2=	MoDsV2FPT0WU
5637	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTF\|Lke3OVkh\|ryP	MnHYV2FPT0WU
LC-1F	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TsUWlEPTB;MUSuNFM2PiEQvF2=	NGjoZVBUSU6JRWK=
SNB75	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTF2LkCzPFMh\|ryP	NFrpN4hUSU6JRWK=
CHP-212	NVfNT4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF2LkC0OlQh\|ryP	NH\PVGRUSU6JRWK=
HT-1376	NIDn[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHqeGhKSzVyPUG0MlEyOjZizszN	M2r6XXNCVkeHUh?=
MONO-MAC-6	NGLHcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XmdmlEPTB;MUSuNVUxOiEQvF2=	NFTrVXRUSU6JRWK=
CA46	M3nrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm2OIJKSzVyPUG0MlE5OjdizszN	NEO1NYRUSU6JRWK=
SCC-15	M2XrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVyyeGR6UUN3ME2xOE42PTh\|IN88US=>	NYqxPI1FW0GQR1XS
ATN-1	M3SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF2Lk[2Nlch\|ryP	NEXqdVRUSU6JRWK=
NCI-H2405	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLJTWM2OD1zND64NVU4KM7:TR?=	MVPTRW5ITVJ?
NCI-H716	NFvVbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7pNXZwUUN3ME2xOE45PDl\|IN88US=>	NHTt[2hUSU6JRWK=
SW620	NHjEboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTF2LkmwNVQh\|ryP	NU\4VVVnW0GQR1XS
NCI-H226	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj2fYE1UUN3ME2xOE46ODh3IN88US=>	NFjQOZVUSU6JRWK=
SW962	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C2NWlEPTB;MUSuPVQ{OiEQvF2=	Ml\5V2FPT0WU
KYSE-150	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPnTWM2OD1zND65OVUh\|ryP	M1m3eXNCVkeHUh?=
OCUB-M	M1juRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnO4TWM2OD1zND65PFg{KM7:TR?=	MnPyV2FPT0WU
ES7	NGnhW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTQe\|dKSzVyPUG1MlA6QDRizszN	MmDWV2FPT0WU
SW1463	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTF3LkSyNlMh\|ryP	M4H0d3NCVkeHUh?=
CAKI-1	NIXGO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XPTWlEPTB;MUWuOVM1PiEQvF2=	MVHTRW5ITVJ?
MKN28	M2P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF3LkW0O\|kh\|ryP	NHfwemdUSU6JRWK=
SW13	NYqzUGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjCNJJSUUN3ME2xOU43OThizszN	M3T4UHNCVkeHUh?=
A3-KAW	NX76OoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfKTWM2OD1zNT65Olk4KM7:TR?=	MomxV2FPT0WU
LU-65	NGDyNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTF3Lkm3Olgh\|ryP	NXjTTWhuW0GQR1XS
Calu-1	M4PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHzUI01UUN3ME2xOk4xOzZ6IN88US=>	M{XUUXNCVkeHUh?=
ST486	NXXNPYRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXMTWM2OD1zNj6wOFMyKM7:TR?=	MoHxV2FPT0WU
BB30-HNC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTF4LkGyOFYh\|ryP	NUC2WGtiW0GQR1XS
EGI-1	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2SyfGlEPTB;MU[uOFQ3KM7:TR?=	MonaV2FPT0WU
SH-4	NX\qNGcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTF4LkS3N\|Eh\|ryP	MULTRW5ITVJ?
MN-60	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTF5LkKyPVch\|ryP	M1\CU3NCVkeHUh?=
MPP-89	M4HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLNbVhqUUN3ME2xO{4zPDV7IN88US=>	M1nNbHNCVkeHUh?=
A2780	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmCzTWM2OD1zNz60NVM6KM7:TR?=	NYDM[5hCW0GQR1XS
Daoy	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PVT2lEPTB;MUeuOFY6PSEQvF2=	MX7TRW5ITVJ?
NCI-H2126	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzydG1KSzVyPUG3MlQ4PzFizszN	NXnpRYhOW0GQR1XS
NCI-H1563	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTF5LkS5NVch\|ryP	Mn\1V2FPT0WU
8-MG-BA	NFezTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nzWWlEPTB;MUeuOlY1QCEQvF2=	M1PLeHNCVkeHUh?=
786-0	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjlSmd3UUN3ME2xO{45OzV\|IN88US=>	NYnBRnY3W0GQR1XS
AM-38	NVGzNXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf4TWM2OD1zNz65N\|A3KM7:TR?=	Mn:yV2FPT0WU
COLO-824	M4DSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHhdVFKSzVyPUG4MlQ1OzZizszN	M1:5TnNCVkeHUh?=
SK-MEL-30	M1PySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTF6LkWwPFIh\|ryP	M1izOHNCVkeHUh?=
CESS	M{fqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13McGlEPTB;MUiuO\|YxQSEQvF2=	MVLTRW5ITVJ?
BL-70	NXn5NW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfJTWM2OD1zOD64NVU3KM7:TR?=	Mlq4V2FPT0WU
NCI-H2170	M{LtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\FRpVKSzVyPUG4MlkyPzlizszN	NFK5Zm9USU6JRWK=
HT-3	NH22PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTyW2QxUUN3ME2xPE46QDNizszN	M3Huc3NCVkeHUh?=
BOKU	NXPyd3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DHZmlEPTB;MUmuNFM5OSEQvF2=	MUfTRW5ITVJ?
HPAF-II	M2PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33VbWlEPTB;MUmuN\|AyPSEQvF2=	NGe5PHBUSU6JRWK=
KGN	NEX5eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTF7LkS3OlUh\|ryP	NIf6Z2tUSU6JRWK=
MC-CAR	NHHxeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;5SVJKSzVyPUG5MlY{OTNizszN	MlHpV2FPT0WU
BHT-101	NGL1WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\jZmlEPTB;MUmuO\|c4KM7:TR?=	MoDoV2FPT0WU
SW1783	NFzBcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXYfZBbUUN3ME2xPU44QDB4IN88US=>	MVHTRW5ITVJ?
KP-N-YN	NF7kbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PqemlEPTB;MkCuNFI3OiEQvF2=	Mn7rV2FPT0WU
LU-165	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OzUmlEPTB;MkCuOVU4OSEQvF2=	MX3TRW5ITVJ?
GOTO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\Yd4pKSzVyPUKwMlY1PTFizszN	MlrxV2FPT0WU
EFM-19	NWrNcpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPDTWM2OD1{MT6wO\|E3KM7:TR?=	MVfTRW5ITVJ?
CTV-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDPeGQ3UUN3ME2yNU4yODV2IN88US=>	MmPhV2FPT0WU
HEL	M3fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;TTWM2OD1{MT60NlE3KM7:TR?=	MVTTRW5ITVJ?
SNU-C2B	NHX0ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjl[VZKSzVyPUKxMlQzPiEQvF2=	MoHXV2FPT0WU
ECC4	NHfaSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHUTWM2OD1{MT63NFch\|ryP	MYTTRW5ITVJ?
NEC8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HjOWlEPTB;MkGuPFM3QCEQvF2=	NGDQT4VUSU6JRWK=
KMOE-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\oZnBKSzVyPUKxMlg6OjFizszN	MX;TRW5ITVJ?
NCI-H524	NInIW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTJ{LkC4NFgh\|ryP	MWXTRW5ITVJ?
WSU-NHL	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTJ{LkG1O\|ch\|ryP	NH:5Z\|dUSU6JRWK=
SF126	M2jiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHkTWM2OD1{Mj6yOFY6KM7:TR?=	NFnoWoRUSU6JRWK=
HOP-92	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[3TWM2OD1{Mj6zNVY4KM7:TR?=	MoGzV2FPT0WU
CTB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fmRWlEPTB;MkKuOFY4PyEQvF2=	MnPZV2FPT0WU
KYSE-270	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrJPFlKSzVyPUKyMlk{PTdizszN	NX;MNmdwW0GQR1XS
SK-MEL-24	NFrERmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPhdpc{UUN3ME2yN{4yQDdizszN	NHzBd3ZUSU6JRWK=
Calu-3	NF7nNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33xfGlEPTB;MkOuNlEzQCEQvF2=	NUjrdHRzW0GQR1XS
GAMG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37QU2lEPTB;MkOuNlM3PyEQvF2=	MVrTRW5ITVJ?
SW1573	NELXPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXMdHRtUUN3ME2yN{44PDF3IN88US=>	MUfTRW5ITVJ?
MHH-NB-11	NIrMTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVf4eoxHUUN3ME2yOE4xOTl2IN88US=>	NFy1NXFUSU6JRWK=
TK10	NULNZo1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjGd2NKSzVyPUK0MlUxOTNizszN	Ml;tV2FPT0WU
LB373-MEL-D	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzEXVZKSzVyPUK0MlYxPjRizszN	NVXrVIVwW0GQR1XS
KALS-1	NH20VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnn[nN2UUN3ME2yOE44OzJ5IN88US=>	NVLKOoF1W0GQR1XS
HUTU-80	NX3XN4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7BTWM2OD1{NT64NFMzKM7:TR?=	M4nQbnNCVkeHUh?=
HuP-T3	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTJ4LkG2O\|Qh\|ryP	NFHFO41USU6JRWK=
OE19	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP5XZhKSzVyPUK2MlIyPTNizszN	M2To[XNCVkeHUh?=
J82	NU\XVnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3uTGNlUUN3ME2yOk4zPDdzIN88US=>	NV72b5Z{W0GQR1XS
DU-4475	NUfuZod{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\KRnJZUUN3ME2yOk4{QDF7IN88US=>	MX;TRW5ITVJ?
DMS-53	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3BTWM2OD1{Nj61NVM5KM7:TR?=	NVn1WpJ5W0GQR1XS
COLO-741	M2mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXpbGZYUUN3ME2yOk45OzR2IN88US=>	MYnTRW5ITVJ?
SW48	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\pXVhRUUN3ME2yOk45QDJizszN	NGf0XHVUSU6JRWK=
IGR-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPRNpFKSzVyPUK2Mlk{OzRizszN	MXfTRW5ITVJ?
639-V	M3PX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\6UGlEPTB;MkeuNFI1PSEQvF2=	NGjpOHhUSU6JRWK=
LK-2	NGXqR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7sTWM2OD1{Nz60NVQyKM7:TR?=	NYL3VGNuW0GQR1XS
NCI-H2347	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJ5Lkm2PVkh\|ryP	MlPVV2FPT0WU
NCI-H2228	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJ6LkC5NFUh\|ryP	MWPTRW5ITVJ?
LS-123	NELMcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTJ6LkGyOlIh\|ryP	NETmTYNUSU6JRWK=
U031	NYTCZWFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17UXmlEPTB;MkiuNlUzKM7:TR?=	MnTIV2FPT0WU
NCI-H1792	NH;q[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJ6LkS3NlEh\|ryP	M1jaPHNCVkeHUh?=
NCI-H2087	M3j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPBcnZKSzVyPUK4Mlc2PTJizszN	NFHEcI5USU6JRWK=
NCI-H2342	M3XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7iNGNHUUN3ME2yPU42OjB6IN88US=>	M3HFXHNCVkeHUh?=
SW626	NUP2eGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITNXZRKSzVyPUK5Mlc2PiEQvF2=	NHXHO3ZUSU6JRWK=
LB2518-MEL	NEfWe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLpe\|NKSzVyPUK5MlgyPSEQvF2=	MX\TRW5ITVJ?
RXF393	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvHTWM2OD1\|MD6wPVUzKM7:TR?=	M{nO[3NCVkeHUh?=
LC4-1	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDYTWM2OD1\|MD6zNFkzKM7:TR?=	M3n4NHNCVkeHUh?=
NCI-H1694	NV20cHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfRTWM2OD1\|MD62OlI1KM7:TR?=	NGGy[VRUSU6JRWK=
K5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTNyLkm3NFIh\|ryP	NXXObFlbW0GQR1XS
HDLM-2	NW\HWHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rNbWlEPTB;M{CuPVczPSEQvF2=	MUPTRW5ITVJ?
BCPAP	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LqSGlEPTB;M{GuPFM4QSEQvF2=	MVjTRW5ITVJ?
BC-3	NVvze2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPX[oZ{UUN3ME2zNk4yPDB\|IN88US=>	Mln3V2FPT0WU
LB996-RCC	M37qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH35cYhKSzVyPUOyMlI{PThizszN	NUDrZ5ZQW0GQR1XS
NCI-H2009	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTN{LkS5PFEh\|ryP	NEPUVFFUSU6JRWK=
HTC-C3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\aTWM2OD1\|Mz63OVE6KM7:TR?=	NWnVOFdzW0GQR1XS
LAMA-84	NYriSXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\nWFRiUUN3ME2zOE41PDB5IN88US=>	MmX1V2FPT0WU
CCRF-CEM	NVrFNJhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\mNGlEPTB;M{SuOVcyPSEQvF2=	Ml20V2FPT0WU
AN3-CA	NYTtOXpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnQeYdVUUN3ME2zOU4xPTZ6IN88US=>	NGnXe4hUSU6JRWK=
NCI-H1734	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLlTWM2OD1\|NT6yOVYyKM7:TR?=	MmXEV2FPT0WU
Ca-Ski	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[3dmlEPTB;M{WuOFExOSEQvF2=	MXPTRW5ITVJ?
U-266	NWm1PIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1i1O2lEPTB;M{WuOlEyPCEQvF2=	NV7JNGZpW0GQR1XS
SBC-5	NFvZVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;1d2lKSzVyPUO1Mlc4QDFizszN	M1HtTXNCVkeHUh?=
GT3TKB	M1;LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:yTWM2OD1\|Nz6xNVUh\|ryP	NVfTS5VQW0GQR1XS
MDA-MB-175-VII	NH61UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPwfFVuUUN3ME2zO{4zOjR6IN88US=>	M1\H[3NCVkeHUh?=
PFSK-1	M1O3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fObmlEPTB;M{euNlQ{PSEQvF2=	MV;TRW5ITVJ?
IMR-5	NIrPOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3QTWM2OD1\|Nz6yOFg4KM7:TR?=	M2ntVXNCVkeHUh?=
Daudi	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PTS2lEPTB;M{euN\|U6PyEQvF2=	M4HGcHNCVkeHUh?=
A498	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD1R3BoUUN3ME2zO{44OjF6IN88US=>	NYDoblh7W0GQR1XS
SCC-4	MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\xTWM2OD1\|Nz63PFQ{KM7:TR?=	M3r6enNCVkeHUh?=
COLO-680N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHITWM2OD1\|OD6yPFg2KM7:TR?=	NH2xRXdUSU6JRWK=
SK-MES-1	NGq5dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[wTWM2OD1\|OD6zNlE2KM7:TR?=	Mnj0V2FPT0WU
SR	NXj4eXNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDobINVUUN3ME2zPE42PDl3IN88US=>	NEXBe\|VUSU6JRWK=
LNCaP-Clone-FGC	NWLsPFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfuVlVnUUN3ME2zPE42PjN5IN88US=>	NFHrXVlUSU6JRWK=
SK-HEP-1	NIe0UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W0V2lEPTB;M{iuO\|gzOiEQvF2=	MX;TRW5ITVJ?
BPH-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPNTWM2OD1\|OD64N\|I6KM7:TR?=	MnPRV2FPT0WU
NCI-H1755	NFzOW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3FTWM2OD1\|OT61PFE4KM7:TR?=	MoTjV2FPT0WU
LXF-289	M{DCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7rTWM2OD1\|OT64NFg1KM7:TR?=	M1jYOnNCVkeHUh?=
SW1088	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1n4bGlEPTB;NECuNlExPyEQvF2=	MUPTRW5ITVJ?
MOLT-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW5eXdjUUN3ME20NE4zQTBzIN88US=>	Mn6yV2FPT0WU
AsPC-1	MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC1OGZoUUN3ME20NE41PTh\|IN88US=>	NE[3WZdUSU6JRWK=
HOP-62	M3PYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjGRnN3UUN3ME20NE43PTZ6IN88US=>	MlnvV2FPT0WU
A172	NFTQcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33wcGlEPTB;NECuPFUyOSEQvF2=	MUjTRW5ITVJ?
SN12C	NHTrToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PZdGlEPTB;NECuPVM5PSEQvF2=	NHfrOZFUSU6JRWK=
MDA-MB-231	NV3vZYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTRyLkm4PVgh\|ryP	Ml61V2FPT0WU
RPMI-2650	NX\xWWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoL3TWM2OD12MT6xOVk{KM7:TR?=	MnftV2FPT0WU
KYSE-140	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HKNWlEPTB;NEGuPFEzOyEQvF2=	M2nBd3NCVkeHUh?=
KINGS-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH4S\|FKSzVyPUSyMlQ3QTdizszN	M2fpO3NCVkeHUh?=
HSC-3	NFrUemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTR{Lk[2OlEh\|ryP	NHG5flFUSU6JRWK=
PC-14	NWTGUJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTPWHZKSzVyPUSzMlE5QDJizszN	NW\uUHprW0GQR1XS
COR-L105	M4\Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTR\|Lk[1NFIh\|ryP	M1WwWnNCVkeHUh?=
BE-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHoTWM2OD12ND6yN\|cyKM7:TR?=	MWrTRW5ITVJ?
NCI-H661	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\QXplKSzVyPUS0MlI6PThizszN	M17zPXNCVkeHUh?=
IST-MEL1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK5PVFKSzVyPUS0MlM2QTlizszN	M3:ySXNCVkeHUh?=
HCC1806	NFrCUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTR2LkW4O\|Mh\|ryP	NIO4WIVUSU6JRWK=
COLO-800	M4jTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTR2Lki0OVMh\|ryP	MV\TRW5ITVJ?
IST-SL2	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fUd2lEPTB;NEWuNVI1PyEQvF2=	NYTaOpdiW0GQR1XS
8305C	M{LLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO4TWM2OD12NT6zNFkh\|ryP	MkjGV2FPT0WU
UACC-62	NGXxSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M164OmlEPTB;NE[uNlg4PSEQvF2=	MmTzV2FPT0WU
COR-L23	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTR5LkG5PUDPxE1?	M4T1cnNCVkeHUh?=
EFE-184	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D5TGlEPTB;NEeuN\|g5KM7:TR?=	NGXPOFRUSU6JRWK=
DMS-114	M{jaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX4TWM2OD12Nz60NVQ6KM7:TR?=	MnHYV2FPT0WU
KYSE-520	NYL1Z3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXOTWM2OD12OD61N\|E2KM7:TR?=	NHT0NVlUSU6JRWK=
SNG-M	M1Hremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2D2bWlEPTB;NEmuOFM1KM7:TR?=	NHP4ZW5USU6JRWK=
A2058	M173Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i5OGlEPTB;NEmuOFg5PSEQvF2=	NWr3UHRZW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Formulation: 25 mM tartaric acid Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324，Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 76 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)

Cited by 76 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Linsitinib (OSI-906) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)